Researchers develop 3D printed ingestible pill

4 Aug 2019

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

A research team led by Tufts University engineers has developed a 3D printed ingestible pill that samples bacteria found in the gut - known as the microbiome - as it passes through the gastrointestinal tract (GI). The ability to profile bacterial species inhabiting the gut could have important implications for the understanding of conditions that affect and are affected by the intestinal microbiome, according to the researchers.

Researchers develop 3D printed ingestible pill
Microbiome sampling pill in the small intestine. (Source: Nano Lab, Tufts University.)

The 3D printed pill described in the journal Advanced Intelligent Systems represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract, according to the researchers. Current methods of sampling the microbiome involve primarily the analysis of fecal DNA and metabolites, but that approach provides little information of the environment upstream of the distal colon, where bacterial species can vary significantly.

The pill has been studied extensively in vitro and in vivo and found to provide accurate identification of bacterial populations and their relative abundance, the paper says. It has been tested in pigs and primates, yet clinical trials will be needed to determine if the pill can be used routinely in humans for clinical care.

More than 1,000 species of bacteria inhabit the healthy gut. The vast majority of these bacteria have a beneficial, supportive role in digestion and protection against disease. When the natural balance of the microbiome is disturbed, a condition called “dysbiosis” occurs, which can be associated with inflammation, susceptibility to infections, and even the exacerbation of other diseases such as cancer. Research is increasingly unveiling specific microbiome metabolites that have beneficial or protective effects against disease.

“We are learning quite a lot about the role of gut microbiome in health and disease. However, we know very little about its biogeography,” said Sameer Sonkusale, professor of electrical and computer engineering at Tufts University’s School of Engineering and corresponding author of the study. “The pill will improve our understanding of the role of spatial distribution in the microbiome profile to advance novel treatments and therapies for a number of diseases and conditions.”

The pill is more sophisticated than just a sponge. It is manufactured in a 3D printer with microfluidic channels that can sample different stages of the GI tract. The surface of the pill is covered with a pH-sensitive coating so that it does not absorb any samples until it enters the small intestine (bypassing the stomach) where the coating dissolves. A semi-permeable membrane separates two chambers in the pill – one containing helical channels that take up the bacteria and the other containing a calcium salt-filled chamber. The salt chamber helps create an osmotic flow across the membrane which pulls the bacteria into the helical channels. A small magnet in the pill enables one to hold it at certain locations in the gut for more spatially targeted sampling using a magnet outside the body. A fluorescent dye in the salt chamber helps locate the pill after it exits the GI tract.

“The design of this device makes it incredibly easy to use, posing little risk to the subject, yet providing so much information,” said Giovanni Widmer, professor of infectious disease and global health at Cummings School of Veterinary Medicine at Tufts University, and co-author of the study responsible for testing the pill's effectiveness in animals and for high throughput sequencing the microbiome samples.

The researchers see this technology as bridging an important gap in understanding the complexity of the ecosystem of the gut. “We have advanced technologies to analyze bacterial populations using DNA sequencing, but until now have not had a way to sample bacteria throughout the GI tract in a way that is not invasive,” said Hojatollah Rezaei Nejad, a post-doctoral fellow studying novel applications of 3D printing in Sonkusale’s laboratory at Tufts and lead author of the study. “By sampling non-invasively, this pill could help us better identify and understand the role of different intestinal bacterial species in health and disease.”

Read More

Related news

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Needle free: Erase wrinkles without injection

Needle free: Erase wrinkles without injection

15 Jul 2019

Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more